NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Drug Manufacturers - Specialty & Generic · USD

Amneal Pharmaceuticals, Inc. (AMRX) Stock Analysis

Amneal Pharmaceuticals, Inc. (AMRX) is a Drug Manufacturers - Specialty & Generic stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

AMRX

$20.20

+$0.36 (+1.81%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare AMRX with… →

AMRX Key Statistics

As of Oct 21, 2026
Trading
Open
$19.90
Previous Close
$19.84
Day's Range
19.73–20.30
52-Week Range
9.99–21.18
Volume
4.66M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.22
Valuation
Market Cap
$7.04B
P/E Ratio
41.22
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
16.94
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
1.82
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
2.26
EPS (ttm)Profit attributable to each share over the last twelve months.
0.49
Financials (FY)
Revenue (FY)
$3.02B+8.05%
Net Income (FY)
$72.06M
Profit marginThe share of revenue left as profit after all costs and taxes.
5.05%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
348.30M
1-Year Return
+96.31%
Dividend and dates
Earnings Date
November 3, 2026
Avg Volume
2.53M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, AMRX closed at $20.20, +96.31% over 1 year.

Amneal Pharmaceuticals, Inc. (AMRX) has a market capitalization of $7.04B.

In fiscal 2025, AMRX reported revenue of $3.02B.

AMRX Stock Return by Calendar Year

Amneal Pharmaceuticals, Inc. (AMRX) return since May 2018: what $10,000 became

1 year
$10,000 $19,631
+96.31%
5 years
$10,000 $35,315
+253.15%
Since May 2018
$10,000 $13,458
+34.58%

If you had invested $10,000 in Amneal Pharmaceuticals, Inc. (AMRX) at the close on May 7, 2018, the earliest close on record here, it would have been worth $13,458 at the close on October 21, 2026: +34.58% in total, +3.57% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+60.32%
2025+59.09%
2024+30.48%
2023+205.03%
2022−58.46%
2021+4.81%
2020−5.19%
2019−64.38%
2018 (partial year)−9.86%

As of October 21, 2026.

AMRX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$3.02B$72.06M2.4%
2024$2.79B−$116.89M−4.2%
2023$2.39B−$83.99M−3.5%
2022$2.21B−$129.99M−5.9%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$3.02B$1.11B$397.91M$72.06M2.4%
2024$2.79B$1.02B$348.37M−$116.89M−4.2%
2023$2.39B$820.57M$238.75M−$83.99M−3.5%
2022$2.21B$784.71M$188.92M−$129.99M−5.9%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

AMRX Valuation vs Drug Manufacturers - Specialty & Generic Median

Median of 97 stocks
MetricAMRXDrug Manufacturers - Specialty & Generic medianvs median
P/E41.2220.31103% above
P/S ratio2.262.107% above
Profit margin5.05%−8.14%13.2 pts above

Medians across 97 Drug Manufacturers - Specialty & Generic stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Amneal Pharmaceuticals, Inc. (AMRX) is capitalised at $7.04B on the latest close. It is classified in the Drug Manufacturers - Specialty & Generic industry, within the Healthcare sector. The company reports 8,700 employees.

The most recent close on file for AMRX is $20.20, dated October 21, 2026. That is +$0.36 (+1.81%) against the previous close. Over the past 52 weeks the price has ranged from $9.99 to $21.18. The latest close sits 102.2% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $3.02B. That is +8.05% against the prior fiscal year, when revenue was $2.79B. Net income for the same year was $72.06M. Profit margin runs at 5.05%. That is 13.2 percentage points above the Drug Manufacturers - Specialty & Generic median of −8.14%. Earnings per share on a trailing basis come to 0.49.

Across the 4 fiscal years on file, revenue moves from $2.21B in 2022 to $3.02B in 2025. Of those 4 years, 1 report positive net income.

Valuation Assessment

AMRX trades at a trailing price-to-earnings ratio of 41.22. That is 102.9% above the Drug Manufacturers - Specialty & Generic median of 20.31. The forward P/E on file is 16.94. The PEG ratio, which sets the P/E against expected earnings growth, reads 1.82. Measured against sales, the shares trade at 2.26 times revenue. On price-to-sales that is 7.47% above the Drug Manufacturers - Specialty & Generic median of 2.1. 97 Drug Manufacturers - Specialty & Generic companies report these metrics, and the medians quoted come from that group.

The reported beta is 1.22. Annualized volatility over the trailing 8 years is 64.29%. The trailing one-year total return is +96.31%. Across 5 years the annualized return works out at +28.70%.

Growth & Income

The record shows no dividend for AMRX.

2026 is still running; the total return is +60.32% year to date. The strongest complete calendar year on file is 2023 at +205.03%; the weakest is 2019 at −64.38%. Of the 7 complete calendar years on file, 4 finished higher.

Peer Comparison

Amneal Pharmaceuticals, Inc. (AMRX) operates in the Drug Manufacturers - Specialty & Generic industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Amneal Pharmaceuticals, Inc. AMRX $7.04B 41.2
Takeda Pharmaceutical Company Limited TAK $63.67B —
Teva Pharmaceutical Industries Limited TEVA $47.37B 67.7
Haleon plc HLN $44.06B 20.5

The Drug Manufacturers - Specialty & Generic industry average P/E ratio is 20.3x. Amneal Pharmaceuticals, Inc. trades at a P/E of 41.2.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Drug Manufacturers - Specialty & Generic Stocks

TAK

Takeda Pharmaceutical Company Limited

$63.67B

 TEVA

Teva Pharmaceutical Industries Limited

$47.37B

 HLN

Haleon plc

$44.06B

 ZTS

Zoetis Inc.

$32.90B

 UTHR

United Therapeutics Corporation

$24.17B

 VTRS

Viatris Inc.

$21.19B
View all Drug Manufacturers - Specialty & Generic stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Amneal Pharmaceuticals, Inc.

Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in the United States, India, Ireland, and internationally. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment offers dosage forms and delivery systems, which include immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, transdermal patches, and topicals. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with a focus on central nervous system and endocrine disorders, including Parkinson's disease. This segment provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid and ONGENTYS for the treatment of hypothyroidism; and CREXONT, which is use for the treatment of Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, retail pharmacies, managed care organizations, purchasing co-ops, hospitals, government agencies, institutions, and pharmaceutical companies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.

Visit website →